We are live on ! Find out more
BVXVW

BiondVax Pharmaceuticals Ltd.
BVXVW

Delisted

BVXVW was delisted on the 13th of May, 2020.

Back to rankings

2 hedge funds and large institutions have $7K invested in BiondVax Pharmaceuticals Ltd. in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VIA
Vantage Investment Advisors
Pennsylvania
+$6.99K
2
UBS Group
UBS Group
Switzerland
+$1.28K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VIA
1
Vantage Investment Advisors
Pennsylvania
$6K +$6.99K +12,000 New
UBS Group
2
UBS Group
Switzerland
$1K +$1.28K +2,200 New

BVXVW Hedge Fund Activity: Q3 2016 in Review

2 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in BiondVax Pharmaceuticals Ltd. (BVXVW) for Q3 2016, worth a combined $7K.

Buyers outnumbered sellers: 2 funds opened new BVXVW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vantage Investment Advisors, opening a new position worth an estimated $6.99K.

  • 2 institutional investors held BiondVax Pharmaceuticals Ltd. (BVXVW) as of Q3 2016, up from 0 in Q2 2016.
  • Funds reported $7K of BiondVax Pharmaceuticals Ltd. stock for Q3 2016.
  • 2 funds opened new BiondVax Pharmaceuticals Ltd. positions in Q3 2016 and 0 closed out, a net change of +2 holders.
  • The largest BiondVax Pharmaceuticals Ltd. buyer in Q3 2016 was Vantage Investment Advisors, an estimated $6.99K added.

Based on aggregated 13F filings for Q3 2016.